Subjective experiences on antipsychotic medications: synthesis and conclusions

被引:35
作者
Marder, SR
机构
[1] W Los Angeles Vet Affairs Med Ctr, Psychiat Serv 116A, MIRECC VISN 22, Los Angeles, CA 90073 USA
[2] Univ Calif Los Angeles, Sch Med, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90024 USA
关键词
schizophrenia; antipsychotics; dysphoria; extrapyramidal symptoms; dopamine;
D O I
10.1111/j.1600-0447.2005.00544.x
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
Objective: This report synthesizes the literature describing the phenomenology, clinical importance and biology of subjective responses to antipsychotic medications in schizophrenia. A patient's experience of an antipsychotic is important because unpleasant or dysphoric responses can impair therapeutic relationships, lead to medication non-adherence, and have direct negative effects on a patient's quality of life. Method: The author selectively reviewed early studies of subjective responses to antipsychotics and integrated this literature with the work of the other investigators in this special section. Results: There is substantial evidence that second-generation antipsychotics have advantages in causing fewer dysphoric responses when compared with first-generation agents. Clinical and neuroimaging studies suggest that dopamine blockade is an important determinant of many of these dysphorias. At this point in time it is unclear whether dysphoria results from extrapyramidal symptoms particularly akathisia and akinesia - or whether they are a direct result of decreased dopamine activity. Conclusion: Clinicians and researchers should continue to monitor dysphorias in schizophrenia. Contributions by the authors in this supplement provide new and more refined methods for measuring subjective responses in future studies.
引用
收藏
页码:43 / 46
页数:4
相关论文
共 23 条
  • [1] Awad AG, 1997, QUAL LIFE RES, V6, P21
  • [2] Quality of life in schizophrenia: Insight and subjective response to neuroleptics
    Browne, S
    Garavan, J
    Gervin, M
    Roe, M
    Larkin, C
    O'Callaghan, E
    [J]. JOURNAL OF NERVOUS AND MENTAL DISEASE, 1998, 186 (02) : 74 - 78
  • [3] Subjective experience and D2 receptor occupancy in patients with recent-onset schizophrenia treated with low-dose olanzapine or haloperidol:: A randomized, double-blind study
    de Haan, L
    van Bruggen, M
    Lavalaye, J
    Booij, J
    Dingemans, PMAJ
    Linszen, D
    [J]. AMERICAN JOURNAL OF PSYCHIATRY, 2003, 160 (02) : 303 - 309
  • [4] Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis
    Geddes, J
    Freemantle, N
    Harrison, P
    Bebbington, P
    [J]. BRITISH MEDICAL JOURNAL, 2000, 321 (7273): : 1371 - 1376
  • [5] AKATHISIA - PREVALENCE AND ASSOCIATED DYSPHORIA IN AN INPATIENT POPULATION WITH CHRONIC-SCHIZOPHRENIA
    HALSTEAD, SM
    BARNES, TRE
    SPELLER, JC
    [J]. BRITISH JOURNAL OF PSYCHIATRY, 1994, 164 : 177 - 183
  • [6] SUBJECTIVE RESPONSE TO NEUROLEPTICS AND OUTCOME IN SCHIZOPHRENIA - A REEXAMINATION COMPARING 2 MEASURES
    HOGAN, TP
    AWAD, AG
    [J]. PSYCHOLOGICAL MEDICINE, 1992, 22 (02) : 347 - 352
  • [7] Maintenance treatment of schizophrenia with risperidone or haloperidol: 2-year outcomes
    Marder, SR
    Glynn, SM
    Wirshing, WC
    Wirshing, DA
    Ross, D
    Widmark, C
    Mintz, J
    Liberman, RP
    Blair, KE
    [J]. AMERICAN JOURNAL OF PSYCHIATRY, 2003, 160 (08) : 1405 - 1412
  • [8] MARDER SR, 1987, ARCH GEN PSYCHIAT, V44, P518
  • [9] Dual diagnosis: A review of etiological theories
    Mueser, KT
    Drake, RE
    Wallach, MA
    [J]. ADDICTIVE BEHAVIORS, 1998, 23 (06) : 717 - 734
  • [10] Improvement of schizophrenic patients' subjective well-being under atypical antipsychotic drugs
    Naber, D
    Moritz, S
    Lambert, M
    Rajonk, F
    Holzbach, R
    Mass, R
    Andresen, B
    Frank, P
    Rüdiger, H
    Reinhard, M
    Burghard, A
    [J]. SCHIZOPHRENIA RESEARCH, 2001, 50 (1-2) : 79 - 88